Folate status is associated with several chronic diseases; thus accurate assessment of folate sta tus has become important in the clinical setting and in epidemiological studies. The diversity of folate forms complicates the task of assaying endogenous folate. We developed and validated an assay that measures various forms of folate in addition to folate catabolites in human serum.
Folate plays important roles in one-carbon metabo lism, including maintenance and repair of DNA and remethylation of homocysteine to methionine. Im paired folate status can cause megaloblastic anemia (1 ) and is a risk factor for neural-tube defects (2 ) . Folate deficiency has also been associated with cardiovascular disease (3 ), dementia (4 ), cognitive impairment (5 ) , and various forms of cancer, including colorectal and breast cancer (6 ) .
The chemical structure of folate consists of a pterin moiety coupled through a methylene group to p-aminobenzoylglutamate (pABG). 4 Folate species differ with respect to the oxidation state of the pterin moiety, the number of glutamate residues connected, and the presence of different one-carbon substituents at the N-5 and/or N-10 position (7 ) .
Folate in serum is present in the monoglutamate form, and the prevailing species is 5-methyltetra hydrofolate (5mTHF) (8, 9 ) . Formyltetrahydrofolate (8, 9 ) and folic acid (FA) can also be present in serum (9 ) , with the latter found only after ingestion of sup plements or fortified food containing FA (9, 10 ) . 5mTHF can be oxidized to 5-methyl-5,6-dihy drofolate under mild oxidation conditions (oxygen). Under more severe conditions (hydrogen peroxide) 5mTHF is oxidized further to a compound originally identified as 4-�-hydroxy-5-methyltetrahydrofolate (hmTHF) (11 ) . Reexamination of the identity of this compound suggested that it has a pyrazino-s-triazine structure (12 ) .
Folate catabolism is a major route of folate turn over in humans and involves cleavage of the C9-N10 bond, producing a pterin and pABG (13 ) . The majority of pABG is N-acetylated to p-acetamidobenzoyl glutamate (apABG) before excretion (13 ) . Several studies have suggested that folate catabolism plays an important role in regulating intracellular folate con centrations, and increased folate catabolism is believed to take place in individuals taking oral contraceptives or anticonvulsant drugs (14 ) .
Serum folate has been measured by various meth ods (15 ) , including chromatographic methods based on HPLC (16, 17 ) , LC-MS (18 -21 ) , and liquid chro matography-tandem mass spectrometry (LC-MS/MS) (9, 22 ) . Despite efforts to establish reliable methods for determining folate status, large interassay and interlaboratory differences have been reported (23) (24) (25) , and each laboratory must establish its own reference intervals.
pABG and apABG in human urine were first iso lated and quantified by McPartlin et al. (13 ) , whose method involved ion exchange and sorbent extraction before HPLC analysis. Recently, pABG and apABG in serum were also measured by use of LC-MS/MS (26 ) .
We describe a selective LC-MS/MS method for si multaneous determination of 5mTHF, hmTHF, FA, 5fTHF, pABG, and apABG in 60 �L of human serum. Sample processing is carried out by a robotic worksta tion, and sample throughput is 192 samples per day.
Materials and Methods

CHEMICALS
5mTHF, FA, 5fTHF, pABG, and ascorbic acid were purchased from Sigma Chemical; 13 C 5 5mTHF, 13 C 5 FA, and 13 C 5 5fTHF were obtained from Merck Eprova AG; and 13 C 2 pABG was from Larodane Fine Chemi cals AB. hmTHF and 13 C 5 hmTHF were prepared from 5mTHF and 13 C 5 5mTHF, respectively, as previously described (11 ) , and apABG and 13 C 2 apABG were pre pared from pABG and 13 C 2 pABG, respectively, as pre viously described (13 ) . Charcoal, mercaptoethanol, phosphoric acid, sodium phosphate, and acetic acid were purchased from Merck, and acetonitrile was from LabScan.
SOLUTIONS AND SAMPLES
Folate species and catabolites were prepared in 20 mmol/L phosphate buffer, pH 7.2. Solutions con taining 5mTHF, 5fTHF, and pABG were supple mented with 56.8 mmol/L ascorbic acid, 8.25 mmol/L mercaptoethanol, and 1.9 mol/L acetonitrile. Solu tions containing hmTHF and FA were supplemented with 56.8 mmol/L ascorbic acid, and solutions con taining apABG supplemented with 8.25 mmol/L mercaptoethanol.
Whole blood from 168 healthy Norwegian blood donors (70% males) with a mean age of 45 years (range 21-69 years) was collected into Vacutainer tubes with no additive. The whole blood samples were kept for 30 min at room temperature before centrifugation and separation of the serum fraction. We obtained 39 se rum samples with increased serum creatinine in the range 130 -957 �mol/L from the routine clinical chem istry laboratory at Haukeland University Hospital. All samples were anonymized and could not be linked back to personal identity. Written consent was ob tained from all blood donors. The study was examined by the institutional review board (REK Vest) and found to be of the quality control category, which under the Norwegian regulations in force is exempt from full re view by the board. Thus the board has no objection to publication of the results.
We prepared folate-free serum by treating serum with activated charcoal (8 mg/mL serum). The char coal was kept in suspension by continuous mixing for 15 min at room temperature, and then centrifuged at 23 500g for 15 min. The treated serum contained no detectable folate (�0.1 nmol/L) as measured by a mi crobiologic assay (27 ) .
All samples and stock solutions were stored at -80 °C. 
INSTRUMENTATION
We used an Agilent series HPLC system (Agilent Tech nologies) equipped with a degasser, a column oven that included a column switcher, a quaternary pump for solvent delivery, and a thermostated autosampler for sample introduction. The HPLC system was coupled to an API 4000 Q Trap (Applied Biosystems/MDS SCIEX) tandem mass spectrometer outfitted with an electrospray ion source (Turbo Ion Spray TM ). Analyst software (Applied Biosystems/MDS SCIEX) was used for HPLC system control and data acquisition and processing. 
LC-MS/MS
Samples were placed in a cooled (4 °C) sample tray and injected into a Zorbax stable bond C8 reversed-phase column [50 � 4.6 mm (i.d.); particle size 3.5 �m] from Agilent Technologies. The column was mounted in the thermostated column compartment set at 20 °C. The flow rate was 1.0 mL/min. The mobile phase consisted of 3 solutions, A � 650 mmol/L acetic acid, B � water, and C � methanol, and was developed according to the following timetable: 0 -0.2 min (70.0% A and 30.0% B), 1.5-2.7 min (3.5% A, 26.5% B, and 70.0% C), 2.8 -3.5 min (3.5% A, 1.5% B, and 95.0% C), and 3.6 -4.8 min (70.0% A and 30.0% B). All gradient steps were linear. The column effluent was directed into the mass spectrometer in the time interval of 1.8 -3.0 min, oth erwise to waste. We optimized acquisition settings by infusion of a 10 �mol/L solution of each analyte at a rate of 1 �L/ min using a Harvard Model 11 syringe pump con nected directly to the ion source by PEEK (polyether ether ketone) tubing. Before entering the mass spec trometer, this solution was mixed at a T-junction with mobile phase delivered at a rate of 1.0 mL/min and with a composition corresponding to the time of elution of the actual analyte.
The ion source temperature (500 °C), the ion spray voltage (5500 V), the collision gas (4 psig), the ion source gas 1 (80 psig), the ion source gas 2 (75 psig), the cell exit potential (10 V), and the activated interface heater were identical for all analytes. Other instrument parameters, mass transitions, and retention times for each compound are detailed in Table 1 . The analytes were detected in the positive ion mode by multiplereaction monitoring.
Matrix effects were assessed by a postcolumn infu sion procedure (28 ) . The analytes (100 �mol/L at a constant flow of 20 �L/min) were directed via a tee to the column effluent, and a prepared serum sample was injected.
LINEARITY AND ASSAY CALIBRATION
We assessed the linear range and limit of quantification (LOQ) by adding the analytes at concentrations of 0.1-140 nmol/L to folate-free serum. Limits of detection (LOD) were defined as the lowest concentrations that gave peaks with signal-to-noise (S/N) ratios of 5, and LOQ were defined as the lowest concentrations that gave peaks with S/N ratios of 10. The S/N ratio was determined as S/N � (peak height -baseline)/SD (baseline), using the S/N script supplied by Applied Biosystems (Analyst Ver. 1.4.1).
For assay calibration we divided pooled serum into 3 portions and added 5mTHF (0, 17, and 62 nmol/ L), hmTHF (3, 9, and 54 nmol/L), and FA, 5fTHF, pABG, and apABG (1, 5, and 50 nmol/L). We estimated the concentration of endogenous 5mTHF to be 8 nmol/L by adding known amounts of 5mTHF to the serum samples and assuming equal recoveries of en dogenous and added 5mTHF and linearity of peak ar eas vs total concentrations. The other analytes were not present above their LOD.
RECOVERY AND ANALYTICAL VARIATION
Folate-free serum and PBS were spiked with 5mTHF, hmTHF, FA, 5fTHF, pABG, or apABG at 3 different concentrations (5, 15 and 45 nmol/L). Twenty repli cates were analyzed at each concentration in 1 analyti cal run. Recovery (%) was calculated by comparing the peak area, corrected by internal standard, in folate-free serum to that in PBS.
For imprecision studies of the assay we used folatefree serum spiked with 3 different concentrations (low, medium, and high) of all the analytes. Intrarun impre cision was determined by measuring 20 replicates of each concentration in 1 day. For interrun imprecision, 10 replicates of each concentration were measured for a 2-week period.
Results and Discussion
SAMPLE PREPARATION
For sample preparation, we added ascorbic acid to the serum sample to avoid oxidation of folate. If any 5mTHF had been oxidized to 5-methyl-5,6 dihydrofolate before sample preparation, it would be reduced back to 5mTHF after the addition of ascorbic acid (29 ) . The samples were deproteinized by acetoni- The traces for the molecular transitions of pABG, 5mTHF, hmTHF, FA, 5fTHF, and apABG corresponding stable isotope-labeled internal standards in blue.
are shown in red, and the trile. Because acetonitrile causes peak broadening on a C8-column, the supernatant was evaporated, and the analytes were redissolved in water.
LC-MS/MS
The folate assay was based on LC-MS/MS and was optimized to determine folate species and folate ca tabolites in serum. The method measures 5mTHF, hmTHF, FA, 5fTHF, pABG, and apABG and the corre sponding 13C-labeled internal standards for all the analytes (Fig. 1) . The analytes were identified by their parent and product ions and by their retention times. All the analytes had the same mass difference between parent and product ion, 147 amu, which corresponds to the loss of the glutamate group. Two analytes, hmTHF and 5fTHF, shared the same ion pair, but use of the other product ions led to a substantial loss of signal. We therefore separated the 2 analytes chromatographically.
We used a mobile phase containing high concen tration of acetic acid (650 mmol/L). There has been a report emphasizing that high signal response in the positive ion mode and efficient separation for a variety of compounds are obtained with a mobile phase con taining a high acetic acid concentration (30 ) . The total run time, which included column equilibration, was 4.8 min. Data acquisition was divided into 2 scan seg ments (0 -2.5 min and 2.5-4.0 min) to obtain opti mized conditions for each analyte.
When stable isotope-labeled analogs are used as internal standards, matrix effects should not affect the 1150 Clinical Chemistry 55: 6 (2009) ratios between efficiencies of ionization of the analyte vs its internal standard (28, 31 ) . However, ion suppres sion may reduce the signal intensity and thereby cause higher imprecision. We therefore assessed the matrix effect by a postcolumn infusion procedure. For all ana lytes, the signal intensities showed a trough from 0.4 -0.7 min, which corresponded to the elution of the sol vent front. Folates and folate catabolites eluted at ) y (cps Intensit longer retention times and in regions with essentially no ion suppression (see Figure S1 in the Data Supple ment that accompanies the online version of this article at http://www.clinchem.org/content/vol55/issue6).
PERFORMANCE OF THE ASSAY
We assessed the LOD, LOQ, and linearity of the assay by analyzing a folate-free serum to which 5mTHF, hmTHF, FA, 5fTHF, pABG, and apABG were added at concentrations of 0.1-140 nmol/L. LOD, LOQ, and linearity data are presented in Table 2 . LOD were in the range of 0.07-0.52 nmol/L, and the assay was linear for all analytes up to 140 nmol/L. Such assay performance allowed the quantification of folate species in serum from patients with folate deficiency (�7.5 nmol/L) as well as adequate folate status.
Recovery was 103%-108% for 5mTHF, 82%-94% for hmTHF, 86%-90% for FA, 91%-98% for 5fTHF, 93%-96% for pABG, and 87%-91% for apABG. Re coveries were independent of analyte concentration, which ranged from 5-45 nmol/L.
The imprecision of the assay was investigated at low, medium, and high concentrations for all 6 analytes ( Table 3 ). The intra-run CVs ranged from 5.0%-9.9%, and the inter-run CVs from 3.3%-9.5%, and assay im precision was comparable to that reported for other folate methods based on LC-MS/MS (9, 32 ) .
DISTRIBUTION OF FOLATE SPECIES
The median (range) of total folate concentration in 168 fresh serum samples from healthy Norwegian blood donors was 19.8 (7.0 -174.0) nmol/L. The median Table 3 . Imprecision of the assay. The high concentration of hmTHF in human se rum was unexpected and has not previously been re ported. hmTHF has been described as an oxidation product of 5mTHF (11 ), and we have detected sub stantial amounts in sera stored at room temperature for weeks or at �20 °C for years. But the samples used for assay validation were stored in the dark on ice for 30 -150 min before centrifugation and separation of the serum fraction, which was then stored at �80 °C for �2 years. The possible existence of hmTHF in vivo should be investigated in future studies, taking partic ular measures to avoid folate oxidation in vitro.
The observation that 5mTHF is the most abun dant folate species in human serum confirms consis tent reports by others (9, 33 ) . The concentration of FA was lower than that detected in US population (in which FA accounted for 8% of total folate) (9 ) , and only 1 of 168 sample donors had FA above 2.0 nmol/L, i.e., 74.8 nmol/L FA. This finding could be explained by the fact that there is no dietary FA fortification in Norway.
MATERIALS AND METHOD COMPARISON
We compared the total concentration of folate in 168 serum samples measured by this LC-MS/MS method with the concentrations measured by a microbiologic method and a newly developed pABG assay (34 ) . These comparisons gave a correlation of r 2 � 0.92 and r 2 � 0.93, respectively (Fig. 2) (35 ) .
FOLATE CATABOLITES
The 2 folate catabolites, pABG and apABG, have been detected in urine (36 ) and have also been reported in the healthy individuals. pABG and apABG showed a positive correlation with total folate (Fig. 3) . In summary, we developed an LC-MS/MS method for the determination of 5mTHF, hmTHF, FA, 5fTHF, pABG, and apABG in human serum. This method is the first reported that allows simultaneous analysis of the 4 different folate species together with serum (26 ) . Our observation of low concentrations of pABG in serum from healthy blood donors (mean 0.07 50 nmol/L) is in disagreement with a previous report of a mean pABG concentration of 8.9 nmol/L in serum pABG apABG from healthy volunteers (26 ) . These results were ob tained with serum samples that were acidified without any antioxidants present. This process is known to lead to partial conversion of folate to pABG (37 ), and we confirmed the presence of similar amounts of pABG in serum subsequent to such sample preparation. Thus, the presence of about 10 nmol/L pABG in serum (27 ) seems to be an artifact related to partial conversion of folate to pABG at low pH. We also measured apABG concentrations (mean 0.47 nmol/L) lower than previ ously reported (mean 3.0 nmol/L) (26 ) . pABG (Spearman R � 0.88, P � 0.001) and apABG (Spear man R � 0.77, P � 0.001) showed a significant correlation with total folate; n � 39.
the folate catabolites in serum. The method also
